SRD001 (inferred)
Heart Failure with Preserved Ejection Fraction (HFpEF)
Key Facts
About Sardocor
Sardocor is a private, clinical-stage biotech subsidiary of the Medera Group, advancing a pipeline of cardiac gene therapies with three active FDA IND approvals. The company leverages foundational science from pioneers who established the cardiac gene therapy field over three decades ago and utilizes a proprietary intracoronary delivery method designed for enhanced efficacy and reduced side effects. Its lead programs target major unmet needs in heart failure (HFpEF and HFrEF) and Duchenne Muscular Dystrophy-associated cardiomyopathy (DMD-CM), with over 1,000 doses of its lead candidate, SRD001, already manufactured. Sardocor is currently pre-revenue and seeking investor partnerships to propel its innovative programs forward.
View full company profileAbout Sardocor
Sardocor is a private, clinical-stage biotech subsidiary of the Medera Group, advancing a pipeline of cardiac gene therapies with three active FDA IND approvals. The company leverages foundational science from pioneers who established the cardiac gene therapy field over three decades ago and utilizes a proprietary intracoronary delivery method designed for enhanced efficacy and reduced side effects. Its lead programs target major unmet needs in heart failure (HFpEF and HFrEF) and Duchenne Muscular Dystrophy-associated cardiomyopathy (DMD-CM), with over 1,000 doses of its lead candidate, SRD001, already manufactured. Sardocor is currently pre-revenue and seeking investor partnerships to propel its innovative programs forward.
View full company profileAbout Sardocor
Sardocor is a private, clinical-stage biotech subsidiary of the Medera Group, advancing a pipeline of cardiac gene therapies with three active FDA IND approvals. The company leverages foundational science from pioneers who established the cardiac gene therapy field over three decades ago and utilizes a proprietary intracoronary delivery method designed for enhanced efficacy and reduced side effects. Its lead programs target major unmet needs in heart failure (HFpEF and HFrEF) and Duchenne Muscular Dystrophy-associated cardiomyopathy (DMD-CM), with over 1,000 doses of its lead candidate, SRD001, already manufactured. Sardocor is currently pre-revenue and seeking investor partnerships to propel its innovative programs forward.
View full company profileTherapeutic Areas
Other Heart Failure with Preserved Ejection Fraction (HFpEF) Drugs
| Drug | Company | Phase |
|---|---|---|
| Barostim™ | CVRx | Clinical Feasibility |
| MANP | E-Star BioTech | Phase 1/2 |
| ALLAY-HF | Alleviant Medical | Pivotal Trial |
| PEGylated Pirfenidone | i-Cordis | Pre-clinical |
| VS-041 | Vasa Therapeutics | Phase 1 |
| Neucardin® | Zensun Sci & Tech | Phase 2 |
| SAVM Procedure | Axon Therapies | Phase 2 |
| STM-01 | Secretome Therapeutics | Phase 1 |